Open-label, phase IIa study investigating the tolerability and pharmacokinetics of testosterone undecanoate [LPCN 1111] in men with hypogonadism
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2014
Price : $35 *
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Lipocine
- 13 Oct 2014 Status changed from recruiting to completed, according to a Lipocine media release.
- 13 Oct 2014 Results published in the Media Release.
- 29 May 2014 New trial record